CORSEARCH
Corsearch, leading provider of brand protection and trademark solutions, has today shared research predicting that the size of the global trade in counterfeit goods could reach €1.67 trillion by 2030, a 75% increase from that of 2023 and a growth 3.6 times higher than predicted for the global economy over the same period.1
Corsearch calculations estimate that counterfeits accounted for 3.3% of global trade in 2023, and will grow to 5% by 2030 - meaning €1 in every €20 spent globally on products could be spent on counterfeit goods.
The total displaced economic activity from counterfeiting in 2022 – namely the cost to brands and manufacturers – totalled €1.02 trillion, resulting in a loss of €162 billion to worldwide sales tax revenue, impacting up to 5.4m jobs.2
In addition to the negative global economic impact of counterfeiting, fake products have a damaging effect on the reputation of brands, reducing customer trust and risking consumer safety.
Corsearch has recognised the need for advanced innovations and solutions in brand protection to meet this challenge, and has today launched its latest technology platform, Corsearch Zeal. The platform uses AI to secure removal of fakes and counterfeit goods from the Internet whilst enabling Corsearch’s team of experts to focus on the most severe issues for brands and consumers and to find the source of the illicit activity.
Using the Corsearch Zeal platform, brands can go further to identify the source of the problem, reducing the losses and harm from counterfeit trade and protecting consumers.
Simon Baggs, President of Brand & Content Protection, Corsearch, commented:
"The rapid expansion of the counterfeiting industry could take up to 5% of the global goods economy by 2030 - posing a significant threat to brands. Urgent measures need to be taken, which is why we are today launching our new Corsearch Zeal platform. Technology enables vast swathes of data to be collated – enabling brands to collaborate to stop online sales whilst also targeting the source of the problem. Without this effort, we estimate that one in twenty euros will be spent on counterfeit goods by 2030, a worrying figure for brands already grappling with the problem in 2024.
“Corsearch Zeal shows our continued dedication to innovation and delivering unrivalled brand protection in the face of this escalating challenge. With Corsearch Zeal and our team of experts, we want to provide the most advanced solutions, enabling brands to work together to protect their consumers.”
For further information on Corsearch Zeal, read more here.
Notes to Editors
Methodology
Corsearch calculations are based on the below datapoints:
-
Total global trade in goods: $31 trillion (UN Conference on Trade & Development) (2023)
Total growth in global trade in goods through 2030: 2.3% (Boston Consulting Group)
Total trade in counterfeit goods, 2023: $1.023 trillion (OECD data) (2023) -
Employment loss: 4.2-5.4 million jobs (Frontier Economics)
Cost of displaced legitimate economic activity due to counterfeiting: $1,106 billion (Frontier Economics & Corsearch calculation) (2022)
Impact on sales tax revenue: $174 billion (Frontier Economics & Corsearch calculation) - 8.3% CAGR in counterfeit trade (Corsearch calculation, based on data from UN Conference on Trade & Development, OECD and EUIPO figures)
For currency conversion into EUR, FX Rates accurate as of 09/05/24
About Corsearch:
Corsearch’s leading Trademark and Brand & Content Protection Solutions are revolutionizing how companies create, monitor, and protect their brands. Over 5,000 businesses worldwide partner with Corsearch to safeguard consumers and their trust in brands — preventing confusion, misrepresentation, and fraud using the hybrid intelligence of advanced AI precision and expert decision of human analysts.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515226927/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom